ACS Launches Major Epidemiology Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

The American Cancer Society (ACS) is launching a 20-year cancer epidemiology study of 500,000 cancer-free adults across the United States. Cancer Prevention Study 3 (CPS-3) will enroll geographically and ethnically diverse participants at 64 of the 4,800 ACS-sponsored Relay for Life events taking place across the country in 2007, and it will continue the accrual process at select Relay events through 2011.

ATLANTA—The American Cancer Society (ACS) is launching a 20-year cancer epidemiology study of 500,000 cancer-free adults across the United States. Cancer Prevention Study 3 (CPS-3) will enroll geographically and ethnically diverse participants at 64 of the 4,800 ACS-sponsored Relay for Life events taking place across the country in 2007, and it will continue the accrual process at select Relay events through 2011. Relay for Life events are "fun run/walk" overnight fundraisers held at schools, fairgrounds, or parks to celebrate survivorship and support ACS research and programs.

Participants in CPS-3 must be between 30 and 65 years of age, must never have been diagnosed with cancer, and must agree to make a long-term commitment to the study. Enrollees complete a brief study questionnaire; investigators measure their waistline and take a small blood sample. Then, for at least 20 years, CPS-3 enrollees will be tracked through questionnaires mailed every few years, identifying and studying factors associated with cancer occurrence or prevention.

The investigators will collect biological specimens from the participants; assess their dietary, lifestyle, and environmental exposures; and conduct active follow-up to discover if and when study participants develop cancer.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content